10-Q: Humana Inc. Q2 2026 Earnings: Strong Premium Growth, Increased Benefits Expense

Humana Inc. reported a significant increase in premiums revenue driven by Medicare membership growth, alongside higher benefits expenses and operating costs for the second quarter of 2026.

Summary

• Humana Inc. reported a substantial increase in total revenues for the second quarter of 2026, reaching $40.87 billion, up 26.2% from $32.39 billion in the same period last year.
• Net income attributable to Humana was $694 million ($5.73 per diluted share) for the quarter, an increase from $545 million ($4.51 per diluted share) in Q2 2025.
• Premiums revenue saw a significant jump of 26.4% to $38.83 billion, primarily due to membership growth in Medicare businesses and higher per-member premiums.
• Benefits expense also rose by 28.3% to $35.37 billion, leading to an increased benefit ratio of 91.1% compared to 89.7% in the prior year's quarter.
• The CenterWell segment demonstrated strong growth with external services revenue up 32.4% to $1.58 billion, driven by primary care and pharmacy solutions.
• The company acquired MaxHealth for approximately $908 million in February 2026, contributing to goodwill and intangible assets.
• Cash and cash equivalents increased to $6.89 billion as of June 30, 2026, from $4.20 billion at the end of 2025, supported by strong operating cash flows.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue and membership growth in key segments, although increased benefit costs and ongoing legal matters warrant attention.

Positives

• Total revenues increased by 26.2% to $40.87 billion in Q2 2026 compared to Q2 2025.
• Net income attributable to Humana increased to $694 million in Q2 2026 from $545 million in Q2 2025.
• Premiums revenue grew by 26.4% to $38.83 billion, driven by Medicare membership growth and higher per-member premiums.
• CenterWell segment's external services revenue increased by 32.4% to $1.58 billion.
• Operating cost ratio improved to 9.8% in Q2 2026 from 11.0% in Q2 2025.
• Cash and cash equivalents increased significantly to $6.89 billion from $4.20 billion.
• Individual Medicare Advantage membership grew by 23.4%.

Negatives

• The consolidated benefit ratio increased to 91.1% in Q2 2026 from 89.7% in Q2 2025, indicating higher claims costs relative to premiums.
• Benefits expense increased by 28.3% to $35.37 billion, outpacing premium revenue growth.
• Net investment income decreased by 7.0% to $253 million.
• The CenterWell segment's operating cost ratio increased to 93.4% for the six-month period ended June 30, 2026, from 92.0% in the prior year period.
• There are ongoing legal proceedings, including a securities litigation case and a TCPA class action lawsuit.

Risks

• The Final RADV Rule, which eliminates the FFS Adjuster and could lead to extrapolated audit results, poses a material adverse effect on results of operations, financial position, or cash flows.
• Ongoing legal proceedings, including securities litigation and TCPA class action, could result in substantial damages, penalties, or sanctions.
• Changes in laws and regulations impacting the healthcare industry, including potential restrictions on profitability, network management, or premium payments, could adversely affect results.
• The company faces risks related to the interpretation and application of Medicare risk-adjustment models and potential audits.
• A downgrade in credit rating could increase interest expenses and impact credit availability.

Future Outlook

The company believes its strategy of offering affordable healthcare with a positive consumer experience in growing markets, centered on an integrated care delivery model, is positioning it for long-term growth in membership and earnings. They expect to incur additional charges over the course of their multi-year transformation program.

Management Comments

• Our strategy is to offer our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics.
• We believe this strategy is positioning us for long-term growth in both membership and earnings.
• We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement.

Industry Context

StockSavvy.ai notes that Humana's Q2 2026 results reflect significant growth in the Medicare Advantage market, a trend consistent with broader industry expansion in government-sponsored health plans. The increased focus on integrated care delivery and value-based arrangements aligns with industry-wide shifts towards more coordinated and cost-effective healthcare solutions.

Comparison to Industry Standards

• Humana's Medicare Advantage membership growth of 23.4% in Individual MA and 27.6% in Group MA significantly outpaces the general growth rate of the US health insurance market.
• The increase in the benefit ratio to 91.1% is a key metric to watch, as it indicates rising healthcare utilization and costs, a challenge faced by many health insurers.
• The company's investment in its CenterWell segment, particularly primary care and pharmacy solutions, mirrors the industry trend of health insurers expanding into care delivery to manage costs and improve patient outcomes.

Legal Proceedings

• Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the U.S. Department of Health and Human Services regarding the Final RADV Rule, which is currently under appeal.
• A putative stockholder class action lawsuit alleges false or misleading statements in SEC filings and statements regarding financial performance, medical costs, and Medicare Advantage business.
• Derivative actions allege breach of fiduciary duty by current and former directors and executive officers.
• A lawsuit challenges the administration of the Medicare Advantage and Part D Star Ratings program.
• The U.S. Department of Justice intervened in a qui tam lawsuit alleging civil violations related to non-commission payments and marketing of Medicare Advantage plans.
• A class action lawsuit alleging violations of the Telephone Consumer Protection Act (TCPA) will proceed in the U.S. District Court, Western District of Kentucky.

Stakeholder Impact

• Shareholders benefit from increased net income and diluted EPS, alongside ongoing share repurchase programs and dividends.
• Members are impacted by the company's focus on integrated care delivery and the potential for improved health outcomes, though rising benefit costs could indirectly affect future premium stability.
• Employees may be affected by the ongoing transformation program and cost-saving initiatives.
• Providers may see increased opportunities for value-based arrangements and integrated care partnerships.

Next Steps

• Continue to execute on the integrated care delivery model to drive long-term growth.
• Manage cost structure and operating model through the ongoing transformation program.
• Monitor and address risks associated with regulatory changes and legal proceedings.
• Utilize available credit facilities and commercial paper programs for liquidity needs.

Key Dates

Recommendation

Humana demonstrates strong revenue and membership growth, particularly in its core Medicare business, and has successfully expanded its CenterWell segment. However, the increasing benefit ratio, ongoing significant legal challenges, and the potential impact of regulatory changes necessitate a cautious approach. While the company is executing on its strategy, the uncertainties warrant a 'hold' recommendation pending further clarity on legal outcomes and sustained improvement in the benefit ratio.

Keywords

Humana, Medicare Advantage, Medicaid, Health Insurance, Healthcare Services, CenterWell, Form 10-Q, Financial Results